CAU
CLMT icon

Caxton Associates (UK)’s Calumet Specialty Products CLMT Stock Holding History

Caxton Associates (UK)’s Portfolio CLMT Stock Details CLMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,435
Closed -$327K – 809
2025
Q4 		$327K Buy
+16,435
New +$316K 0.01% 597

Other funds holding CLMT

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WDOM
Wasserstein Debt Opportunities Management New York $189M AUM 169.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Caxton Associates (UK)'s CLMT Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Calumet Specialty Products (CLMT) in Q1 2026, closing a stake of 16,435 shares — an estimated $327K sold.

Caxton Associates (UK) first reported a position in CLMT in Q4 2025 and held it in 1 quarter. The position peaked at $327K in Q4 2025. 180 funds tracked by Wall St. Rank hold CLMT as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Calumet Specialty Products position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 16,435 Calumet Specialty Products shares in Q1 2026, an estimated $327K.
  • Caxton Associates (UK) first reported a position in Calumet Specialty Products in Q4 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Calumet Specialty Products position peaked at $327K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.